Vaccines
Scientists at University of Navarra Describe Research in Vaccines
Published in Vaccine Weekly, August 31st, 2011
2011 AUG 31 -- "Despite having been the first cancer vaccine to provide clear-cut evidence of biological and clinical efficacy as well as of clinical benefit in humans, idiotype vaccines have failed to become the first therapeutic cancer vaccine to be granted regulatory approval. Indeed, idiotypic vaccination is still an experimental therapeutic option for some types of B-cell malignancy over 20 years after its first use in patients with lymphoma," researchers in Pamplona, Spain report.
"The ultimate reason for this situation lies in the recent failure of three large-scale, independent, randomized trials to achieve their respective main clinical end points....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2011-08-31)
More Articles from Vaccine Weekly
- Pediatric Vaccines
Scientists at GlaxoSmithKline Target Pediatric Vaccines - Salmonella
Studies from Yale University School of Medicine Provide New Data on Salmonella - Influenza Vaccines
Cork University Publishes Research in Influenza Vaccines - Diabetes
Data on Diabetes Published by Researchers at University of Nottingham - Encephalitis
Data on Encephalitis Discussed by B.Y. Si and Colleagues - Ovarian Cancer
Data on Ovarian Cancer Detailed by Researchers at Osaka University - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
